Evaxion Biotech A/S (EVAX) News Today $0.62 -0.20 (-24.48%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$0.55▼$0.7750-Day Range$0.62▼$1.1752-Week Range$0.47▼$2.44Volume763,628 shsAverage Volume275,507 shsMarket Capitalization$17.23 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineShort Interest in Evaxion Biotech A/S (NASDAQ:EVAX) Declines By 22.8%americanbankingnews.com - December 3 at 1:42 AMEvaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Conceptfinance.yahoo.com - November 28 at 8:40 AMEvaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapyfinance.yahoo.com - November 15 at 8:55 AMADRs End Lower; Evaxion Biotech A/S Declines 30%morningstar.com - November 9 at 6:19 PMEvaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattakfinance.yahoo.com - November 6 at 2:49 PMADRs Hold Steady; Fresh2 Group Climbs 23%morningstar.com - October 31 at 6:20 PMEvaxion Biotech: Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01finanznachrichten.de - October 31 at 1:20 PMEvaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01finance.yahoo.com - October 31 at 1:20 PMEvaxion Biotech: New and Exciting Clinical Data on Evaxion's AI-Immunology-Based Personalized Cancer Vaccines to be Presentedfinanznachrichten.de - October 26 at 1:07 PMNew and Exciting Clinical Data on Evaxion's AI-Immunology™-Based Personalized Cancer Vaccines to be Presentedtmcnet.com - October 26 at 1:07 PMNew and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presentedfinance.yahoo.com - October 26 at 1:07 PMEvaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiencyfinance.yahoo.com - October 5 at 10:00 AMEvaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jabfinance.yahoo.com - September 21 at 5:11 PMEvaxion Biotech: Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrheafinanznachrichten.de - September 20 at 3:29 PMEvaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrheafinance.yahoo.com - September 20 at 10:29 AMEvaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical companyfinance.yahoo.com - September 18 at 10:08 AMNovo Buys Embark Biotech to Find New Avenues for Weight Lossbloomberg.com - August 30 at 8:00 AMEvaxion Biotech: Evaxion announces Executive Management Changes to strengthen the AI-strategyfinanznachrichten.de - August 29 at 11:57 AMEvaxion announces Executive Management Changes to strengthen the AI-strategyfinance.yahoo.com - August 29 at 11:57 AMEuropean Equities Traded in the US as American Depositary Receipts Rising, Backed by Mostly Firmer Marketsmsn.com - August 24 at 8:57 AMEvaxion Biotech A/S (NASDAQ:EVAX) Q2 2023 Earnings Call Transcriptfinance.yahoo.com - August 23 at 5:48 PMQ2 2023 Evaxion Biotech A/S Earnings Callfinance.yahoo.com - August 23 at 3:22 AMEvaxion Biotech: Evaxion Announces Business Update and Second Quarter 2023 Financial Resultsfinanznachrichten.de - August 18 at 5:57 PMEvaxion Announces Business Update and Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 18 at 5:57 PMEvaxion Biotech: Personalized Cancer Vaccine Biotech With Q4 2023 Catalystmsn.com - August 3 at 12:11 PMEvaxion gets $20M financing from Negmamsn.com - August 1 at 9:43 PMEvaxion announces financing commitments totaling up to USD 20 million with Negma Groupfinance.yahoo.com - August 1 at 11:30 AMEvaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureusfinance.yahoo.com - July 31 at 11:44 AMIovance Biotherapeutics: More Than A One-Shot Wonderseekingalpha.com - July 10 at 10:46 PMThermo Fisher to buy Audax’s CorEvitas for $913Maxios.com - July 8 at 3:19 AMCancer drug firms soar as positive clinical trial data ignites investor excitementfoxnews.com - June 8 at 11:49 AMADRs End Mostly Lower, BiondVax, Evaxion Biotech Trade Activelymarketwatch.com - June 5 at 10:01 PMCancer drugmakers rise as industry meet fuels investor interestnews.yahoo.com - June 5 at 12:01 PMEvaxion Biotech Shares Rise 38% After Positive EVX-01 Phase 1 Trial Datamarketwatch.com - June 5 at 12:01 PMWhy Are Evaxion Biotech Shares Trading Higher Todayfinance.yahoo.com - June 5 at 12:01 PMEvaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trialfinance.yahoo.com - June 3 at 9:03 PMEuropean Equities Recover Some Losses in Thursday Tradingmsn.com - June 1 at 1:16 PMAnalysts Expect Breakeven For Evaxion Biotech A/S (NASDAQ:EVAX) Before Longfinance.yahoo.com - June 1 at 8:15 AMEvaxion Announces Business Update and First Quarter 2023 Financial Resultsfinance.yahoo.com - May 31 at 11:04 AMEvaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01finance.yahoo.com - May 25 at 7:09 PMElan's Martin Named Worst Biotech CEO of '08thestreet.com - May 21 at 8:29 PMEvaxion to host R&D Day on May 25, 2023finance.yahoo.com - May 16 at 8:49 AMFourth quarter and full year 2022 financial results and business updatefinance.yahoo.com - April 27 at 9:51 AMEvaxion Biotech Says Personalized Cancer Immunotherapy Meets Primary Endpoint In Melanoma Patientsmsn.com - April 18 at 9:21 PMEvaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpointsfinance.yahoo.com - April 18 at 9:57 AMEvaxion Biotech: Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platformfinanznachrichten.de - April 14 at 6:53 PMEvaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platformfinance.yahoo.com - April 13 at 12:51 PMLake Street Keeps Their Buy Rating on Evaxion Biotech (EVAX)markets.businessinsider.com - March 31 at 12:47 PMEvaxion Biotech: Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patientsfinanznachrichten.de - March 28 at 10:31 AMEvaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patientsfinance.yahoo.com - March 28 at 10:31 AM Get Evaxion Biotech A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address EVAX Media Mentions By Week EVAX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EVAX News Sentiment▼0.930.39▲Average Medical News Sentiment EVAX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EVAX Articles This Week▼21▲EVAX Articles Average Week Get Evaxion Biotech A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PHAXIAM Therapeutics News Today Protara Therapeutics News Today Senti Biosciences News Today Aptose Biosciences News Today Brainstorm Cell Therapeutics News Today Eiger BioPharmaceuticals News Today PharmaCyte Biotech News Today Entera Bio News Today Acorda Therapeutics News Today Sorrento Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:EVAX) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion Biotech A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.